Haemonetics Corporation (NYSE:HAE) Stock Has Average Target Price of $99.78 According to Brokerages

Shares of Haemonetics Corporation (NYSE:HAE) have earned a consensus rating of “Moderate Buy” from the eleven brokerages that are covering the company, MarketBeat reports. Four investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $102.00.

A number of research analysts recently commented on the stock. Robert W. Baird increased their target price on shares of Haemonetics from $96.00 to $119.00 and gave the company an “outperform” rating in a research report on Friday, August 21st. BTIG Research boosted their price target on shares of Haemonetics from $110.00 to $130.00 and gave the company a “buy” rating in a research report on Thursday. Wall Street Zen upgraded shares of Haemonetics from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 8th. Raymond James Financial raised their price objective on Haemonetics from $105.00 to $125.00 and gave the stock an “outperform” rating in a report on Thursday, September 3rd. Finally, Citigroup lifted their target price on Haemonetics from $79.00 to $92.00 and gave the stock a “neutral” rating in a research report on Friday, August 7th.

Institutional Investors Weigh In On Haemonetics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in HAE. Nierenberg Investment Management Company LLC acquired a new position in Haemonetics in the second quarter valued at $1,971,000. Rice Hall James & Associates LLC acquired a new stake in shares of Haemonetics during the second quarter worth about $3,828,000. Renaissance Technologies LLC acquired a new stake in shares of Haemonetics during the first quarter worth about $2,435,000. Quantinno Capital Management LP boosted its stake in shares of Haemonetics by 438.0% during the first quarter. Quantinno Capital Management LP now owns 30,708 shares of the medical instruments supplier’s stock worth $1,731,000 after buying an additional 25,000 shares during the period. Finally, Aurora Investment Counsel purchased a new position in shares of Haemonetics during the second quarter worth about $1,913,000. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Key Headlines Impacting Haemonetics

Here are the key news stories impacting Haemonetics this week:

• Positive Sentiment: CSL plans a large-scale rollout of Haemonetics equipment. CSL expects to deploy Haemonetics’ NexSys PCS plasmapheresis devices, Persona PLUS technology and related disposables across more than 300 existing U.S. plasma-collection centers by the end of 2027. The expansion is substantially larger than the previously understood scope of the supply relationship and could create a more significant recurring revenue opportunity for Haemonetics. Haemonetics Stock Surges as Plasma Deal Opens Door to More Revenue
• Positive Sentiment: The agreement improves visibility into future demand. Haemonetics disclosed a non-exclusive supply agreement with CSL Plasma, giving investors greater confidence in future device and consumables sales. While the companies did not disclose detailed financial terms, the planned rollout supports the outlook for continued growth in Haemonetics’ plasma business. Haemonetics Expands NexSys PCS Deployment with CSL Plasma
• Positive Sentiment: Analyst sentiment also improved. BTIG reportedly raised its price target to $130, adding to the bullish reaction and reinforcing expectations that the CSL expansion could support Haemonetics’ earnings trajectory. Separate coverage cited fiscal 2027 guidance for reported revenue growth of 4% to 7%, organic growth of 3% to 6% and operating-margin expansion of 50 to 100 basis points. Haemonetics Stock Breaks Higher With November Test Looming
• Neutral Sentiment: Execution and timing remain important. The rollout is scheduled through the end of 2027, so the revenue benefit is likely to build gradually rather than appear immediately. The agreement is also non-exclusive, and the company’s elevated valuation following the rally leaves the stock more sensitive to delays, weaker plasma-collection demand or disappointing financial guidance.

Haemonetics Stock Up 17.3%

Haemonetics stock opened at $119.29 on Friday. Haemonetics has a 1-year low of $48.17 and a 1-year high of $121.00. The company has a debt-to-equity ratio of 1.40, a current ratio of 3.08 and a quick ratio of 1.91. The stock has a market cap of $5.43 billion, a PE ratio of 58.47, a P/E/G ratio of 2.04 and a beta of 0.61. The stock’s fifty day moving average is $101.33 and its two-hundred day moving average is $79.09.

Haemonetics (NYSE:HAE) last announced its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $1.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.08 by $0.06. The company had revenue of $339.38 million during the quarter, compared to the consensus estimate of $327.86 million. Haemonetics had a return on equity of 27.55% and a net margin of 7.12%.Haemonetics’s revenue for the quarter was up 5.5% on a year-over-year basis. During the same period in the previous year, the business earned $1.10 EPS. On average, sell-side analysts expect that Haemonetics will post 5.29 EPS for the current fiscal year.

About Haemonetics

Haemonetics Corporation (NYSE: HAE) is a medical technology company that develops and supplies products and software for blood management. Its solutions are used to collect, process, manage and analyze blood and blood components, helping healthcare providers and blood and plasma collection organizations improve the availability, safety and efficiency of transfusion-related care.

The company’s portfolio includes plasma and blood component collection systems, disposable collection and processing kits, surgical blood recovery and autotransfusion systems, and technologies used to assess coagulation and hemostasis.